Share 'Sarepta Exon Skipping 45 amenable - limited or no ambulation dose titration study is recruiting'
Sarepta is running a trial at 3 sites recruiting a total of 12 patients for a dose escalation study of 12 weeks followed by open label extension of their exon skipping 45 drug SRP-4045 for boys who are non-ambulatory or have limited ambulation (age 7 to 21). The clinical gov link for the study is https://clinicaltrials.gov/ct2/show/NCT02530905?term=sarepta+duchenne&rank=2
You can share this discussion in two ways…
Share this link:
Send it with your computer's email program: Email this